Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.67 and traded as high as $6.75. Capricor Therapeutics shares last traded at $6.47, with a volume of 172,136 shares.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. StockNews.com initiated coverage on shares of Capricor Therapeutics in a research report on Thursday, August 17th. They set a “sell” rating for the company. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, August 15th.
Capricor Therapeutics Stock Up 0.2 %
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.05. Capricor Therapeutics had a negative net margin of 309.05% and a negative return on equity of 323.39%. The firm had revenue of $3.92 million for the quarter. On average, analysts predict that Capricor Therapeutics Inc will post -1.26 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in CAPR. Tower Research Capital LLC TRC lifted its position in shares of Capricor Therapeutics by 138.7% during the first quarter. Tower Research Capital LLC TRC now owns 8,770 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 5,096 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Capricor Therapeutics during the third quarter valued at about $61,000. Charles Schwab Investment Management Inc. bought a new position in shares of Capricor Therapeutics during the first quarter valued at about $57,000. Virtu Financial LLC bought a new position in shares of Capricor Therapeutics during the first quarter valued at about $71,000. Finally, HighTower Advisors LLC lifted its position in shares of Capricor Therapeutics by 17.8% during the fourth quarter. HighTower Advisors LLC now owns 19,885 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 3,001 shares in the last quarter. 10.18% of the stock is owned by institutional investors.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
- Five stocks we like better than Capricor Therapeutics
- Financial Services Stocks Investing
- Is Enbridge Stock Too Cheap to Pass Up Now?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 5 Best REIT Alternatives for Passive Real Estate Income
- How Can Investors Use the Dogs of the Dow Strategy?
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.